Company: TELO
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-023970
Chunk: 63

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 2
Chunk 63
---
 June 30, 

    2025  
    2024 
  
    Net cash provided by (used in): 

    Operating activities 
    $(1,559,577) 
    $(3,462,258)
  
    Financing activities 
     1,047,769  
     5,344,936 
  
    Net change in cash 
    $(511,808) 
    $1,882,678 

Net
Cash from Operating Activities

The
cash used in operating activities resulted primarily from our net losses, stock-based compensation expenses and changes in components
of accounts payable, accrued liabilities, and prepaid expenses.

For
the six months ended June 30, 2025, operating activities used $1.6 million of cash, primarily due to a net loss of $7.2 million,
stock compensation costs of $6.0 million and by a $0.4 million change in accounts payable, accrued liabilities and prepaid expenses.
Accounts payable, accrued and prepaid expenses was primarily composed of research and development payables, consultant costs,
insurance costs, legal and accounting expenses.

For
the six months ended June 30, 2024, operating activities used $3.5 million of cash, primarily due to a net loss of $7.7 million offset
by $0.1 million change in accounts payable, accrued and prepaid expenses. Accounts payable, accrued and prepaid expenses was primarily
composed of research and development payables, consultant costs, insurance costs, legal and accounting expenses.

Net
Cash from Financing Activities

For
the six months ended June 30, 2025, financing activities provided $1.0 million of cash, resulting primarily from proceeds from sale of
common stock.

For
the six months ended June 30, 2024, financing activities provided $5.3 million of cash, resulting primarily from $5.8 million in proceeds
from sale of common stock, less offering costs, offset by $0.5 million payments to related parties, and $0.1 million of repayments under
related party line of credit.

Item
3. Quantitative and Qualitative Disclosures About Market Risk

We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and therefore are not required to provide the information
under this item per Item 305(e) of Regulation S-K.

Item
4. Controls and Procedures

Evaluation
of Disclosure Controls and Procedures

As
of the